Synthesis, anticonvulsant properties and 5-HT1A/5-HT2A receptor affinity of new N-[(4-arylpiperazin-1-yl)-propyl]-2-aza-spiro[4.4]nonane and [4.5]decane-1,3-dione derivatives.

作者: Jolanta Obniska , Małgorzata Dybała , Andrzej J Bojarski , Marcin Kołaczkowski , Sijka Charakchieva-Minol

DOI:

关键词:

摘要: A series of twenty new N-[(4-arylpiperazin-1-yl)-propyl]-2-aza-spiro[4.4]nonane- and [4.5]decane-1,3-dione derivatives were synthesized their anticonvulsant activity was evaluated in maximal electroshock (MES) sc pentertazole (sc PTZ) tests. Their neurotoxicity examined as well. Although no antiseizure properties the investigated compounds found MES model, eight them active PTZ test three, namely 2-{3-[4-(2-fluorophenyl)-piperazin-1yl]-propyl}-2-aza-spiro[4.4]nonane-1,3-dione (7), 2-{3-[4-(2-fluorophenyl)-piperazin-1-yl]-propyl}-7-methyl-2-aza-spiro[4.5]-decane-1,3- dione (22) 2-{3-[4-(3-chlorophenyl)-piperazin-1-yl]-propyl}-7-methyl-2-aza-spiro[4.5]-decane-1,3-dione (23) classified to Anticonvulsant Screening Program (ASP) 1 class. In addition, since belong a class long-chain arylpiperazines, serotonin 5-HT1A 5-HT2A receptor affinity determined. All 2-OCH3 3-Cl most potent ligands (Ki = 24-143 70-107 nM, respectively), whereas highest observed for unsubstituted 8-66 nM). No correlation between serotonergic observed.

参考文章(27)
Michael A. Rogawski, Principles of Antiepileptic Drug Action ,(2002)
Richard A. Glennon, Noreen A. Naiman, Robert A. Lyon, Milt Titeler, Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands. Journal of Medicinal Chemistry. ,vol. 31, pp. 1968- 1971 ,(1988) , 10.1021/JM00118A018
Yuji Wada, Mitsuhiko Nakamura, Hidehiro Hasegawa, Nariyoshi Yamaguchi, Intra-hippocampal injection of 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) inhibits partial and generalized seizures induced by kindling stimulation in cats Neuroscience Letters. ,vol. 159, pp. 179- 182 ,(1993) , 10.1016/0304-3940(93)90828-9
Emilio Perucca, The new generation of antiepileptic drugs: advantages and disadvantages British Journal of Clinical Pharmacology. ,vol. 42, pp. 531- 543 ,(1996) , 10.1111/J.1365-2125.1996.TB00107.X